Schedule III Is Nothing to Celebrate
That is the date the United States government was granted U.S. Patent No. 6,630,507 for cannabinoids, formally recognizing them as compounds with medical value, including antioxidant and neuroprotective properties with potential applications in conditions such as Alzheimer’s disease, Parkinson’s disease, and stroke.